XML 60 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Quarterly Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]    
Quarterly Data (Unaudited) Table
 
 
2018
 
 
First
 
Second
 
Third
 
Fourth
 
Total
 
 
(In Millions, Except Per Share Data)
Net operating revenues
 
$
1,046.0

 
$
1,067.7

 
$
1,067.6

 
$
1,096.0

 
$
4,277.3

Operating earnings (a)
 
150.0

 
157.3

 
154.5

 
93.4

 
555.2

Provision for income tax expense
 
30.0

 
29.3

 
30.2

 
29.4

 
118.9

Income from continuing operations
 
105.7

 
113.0

 
109.4

 
46.2

 
374.3

(Loss) income from discontinued operations, net of tax
 
(0.5
)
 
0.2

 
(0.1
)
 
1.5

 
1.1

Net income
 
105.2

 
113.2

 
109.3

 
47.7

 
375.4

Less: Net income attributable to noncontrolling interests
 
(21.4
)
 
(21.4
)
 
(20.7
)
 
(19.6
)
 
(83.1
)
Net income attributable to Encompass Health
 
$
83.8

 
$
91.8

 
$
88.6

 
$
28.1

 
$
292.3

Earnings per common share:
 
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Encompass Health common shareholders: (b)
 
 
 
 
 
 
 
 
 
 
Continuing operations
 
$
0.86

 
$
0.93

 
$
0.90

 
$
0.27

 
$
2.97

Discontinued operations
 
(0.01
)
 
—

 
—

 
0.02

 
0.01

Net income
 
$
0.85

 
$
0.93

 
$
0.90

 
$
0.29

 
$
2.98

Diluted earnings per share attributable to Encompass Health common shareholders: (b)
 
 
 
 
 
 
 
 
 
 
Continuing operations
 
$
0.85

 
$
0.92

 
$
0.89

 
$
0.26

 
$
2.92

Discontinued operations
 
(0.01
)
 
—

 
—

 
0.02

 
0.01

Net income
 
$
0.84

 
$
0.92

 
$
0.89

 
$
0.28

 
$
2.93


(a) 
We define operating earnings as income from continuing operations attributable to Encompass Health before (1) loss on early extinguishment of debt; (2) interest expense and amortization of debt discounts and fees; (3) other income; and (4) income tax expense.
(b)  
Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.
 
 
2017
 
 
First
 
Second
 
Third
 
Fourth
 
Total
 
 
(In Millions, Except Per Share Data)
Net operating revenues
 
$
957.1

 
$
966.4

 
$
981.6

 
$
1,008.8

 
$
3,913.9

Operating earnings (a)
 
147.1

 
141.3

 
145.2

 
144.7

 
578.3

Provision for income tax expense (b)
 
39.7

 
28.6

 
43.1

 
34.4

 
145.8

Income from continuing operations (b)
 
84.7

 
79.2

 
85.2

 
101.5

 
350.6

(Loss) income from discontinued operations, net of tax
 
(0.3
)
 
0.2

 
(0.1
)
 
(0.2
)
 
(0.4
)
Net income (b)
 
84.4

 
79.4

 
85.1

 
101.3

 
350.2

Less: Net income attributable to noncontrolling interests
 
(17.6
)
 
(16.4
)
 
(19.2
)
 
(25.9
)
 
(79.1
)
Net income attributable to Encompass Health (b)
 
$
66.8

 
$
63.0

 
$
65.9

 
$
75.4

 
$
271.1

Earnings per common share:
 
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Encompass Health common shareholders: (b) (c)
 
 
 
 
 
 
 
 
 
 
Continuing operations
 
$
0.75

 
$
0.70

 
$
0.67

 
$
0.77

 
$
2.88

Discontinued operations
 
—

 
—

 
—

 
—

 
—

Net income
 
$
0.75

 
$
0.70

 
$
0.67

 
$
0.77

 
$
2.88

Diluted earnings per share attributable to Encompass Health common shareholders: (b) (c) (d)
 
 
 
 
 
 
 
 
 
 
Continuing operations
 
$
0.70

 
$
0.70

 
$
0.67

 
$
0.76

 
$
2.84

Discontinued operations
 
—

 
—

 
—

 
—

 
—

Net income
 
$
0.70

 
$
0.70

 
$
0.67

 
$
0.76

 
$
2.84


(a) 
We define operating earnings as income from continuing operations attributable to Encompass Health before (1) loss on early extinguishment of debt; (2) interest expense and amortization of debt discounts and fees; (3) other income; and (4) income tax expense.
(b)  
During the preparation of our December 31, 2018 financial statements, an error was identified in the accounting for deferred tax assets as described further in Note 1, Summary of Significant Accounting Policies, “Revision of Previously Issued Financial Statements.” The financial results included in the table above reflects the revision of our quarterly results for the three months and year ended December 31, 2017 to reflect the $14.8 million reduction in our Provision for income tax expense as shown in the table below. The revision of unaudited financial statements for the quarter and year-to-date periods ended March 31, June 30, and September 30, 2018 related to the statement of shareholders’ equity, will be affected in connection with the filing of our 2019 Form 10-Qs.
 
As Reported
 
Adjustment
 
As Revised
For the Three Months Ended December 31, 2017
(In Millions, Except Per Share Data)
Provision for income tax expense
$
49.2

 
$
(14.8
)
 
$
34.4

Income from continuing operations
86.7

 
14.8

 
101.5

Net income
86.5

 
14.8

 
101.3

Net income attributable to Encompass Health
60.6

 
14.8

 
75.4

Basic earnings per share attributable to Encompass Health common shareholders
0.62

 
0.15

 
0.77

Diluted earnings per share attributable to Encompass Health common shareholders
0.61

 
0.15

 
0.76

(c)  
Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.
(d)  
For the second quarter of 2017, adding back the loss on extinguishment of convertible debt, net of tax to our Income from continuing operations attributable to Encompass Health common shareholders causes a per share increase when calculating diluted earnings per common share resulting in an antidilutive per share amount. Therefore, basic and diluted earnings per common share are the same for the three months ended June 30, 2017.